Produits et services

Non-medicated preparations for body and beauty care. Medicinal preparations; pharmaceuticals; medicated nasal spray preparations; biochemical preparations for medical use; non-medical nasal sprays.

Produits et services

Pharmaceutical and medical preparations, namely medicated nasal spray preparations, medicated throat sprays, medicated mouth sprays, medicated sprays for wound care, medicated skin sprays, medicated lotions and creams for wound and skin care, medicated ear sprays and throat lozenges.

Abrégé

The present invention relates to a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof as active ingredient for use in treating and/or preventing a skin disease. The invention also relates to a method for treating and/or preventing a skin disease of a patient, the method comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof. Furthermore, the invention provides cosmetic uses of a composition comprising a carboxylic acid or a salt thereof for reducing redness of the skin, skin lesions, wrinkles, impurities or irregularities of the skin. In addition, the present invention relates to a pharmaceutical composition comprising as active ingredient a carboxylic acid or a pharmaceutically acceptable salt thereof for use in improving barrier function of the skin, wherein the pharmaceutical composition is administered to an infant and a method for treating and/or preventing a skin disease of a patient, the method comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 17/04 - Antiprurigineux

Abrégé

The present invention relates to a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof as active ingredient for use in treating and/or alleviating and/or preventing nasal congestion, a viral infectious disease of the respiratory tract or an inflammation of the throat. Furthermore, the present invention relates to a method for treating and/or alleviating and/or preventing nasal congestion, viral infections of the respiratory tract and/or inflammation of the throat in. a patient, comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof. In addition, the present invention relates to a method for alleviating the symptoms associated with nasal congestion, viral infections of the respiratory tract and/or inflammation of the throat comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 11/02 - Agents rhinologiques, p. ex. décongestionnants
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge

Abrégé

The present invention relates to a pharmaceutical composition comprising as active ingredient a carboxylic acid or a pharmaceutically acceptable salt thereof for use in improving barrier function of the skin, wherein the pharmaceutical composition is administered to an infant. The invention also relates to a method for treating and/or preventing a skin disease of a patient, the method comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 17/16 - Émollients ou protecteurs, p. ex. contre les radiations
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques

Abrégé

The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
• A61K 31/25 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques avec des alcools polyoxyalkylés, p. ex. esters de polyéthylèneglycol
• A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine

Abrégé

The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.

Classes IPC  ?

• A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
• A61K 31/25 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques avec des alcools polyoxyalkylés, p. ex. esters de polyéthylèneglycol

Abrégé

The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
• A61K 31/25 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques avec des alcools polyoxyalkylés, p. ex. esters de polyéthylèneglycol
• A61P 11/06 - Antiasthmatiques
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 37/02 - Immunomodulateurs
• A61P 37/08 - Agents antiallergiques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
• A61K 31/25 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques avec des alcools polyoxyalkylés, p. ex. esters de polyéthylèneglycol
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 11/06 - Antiasthmatiques
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 37/02 - Immunomodulateurs
• A61P 37/08 - Agents antiallergiques

Abrégé

The present invention relates to short chain fatty acids (SCFA) for modulating a Th2 immune response towards a Th1 immune response for prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders, particularly of a disease or disorder mediated by T helper 2 (Th2) cell-derived cytokines, including, without being limited to, !L-4. IL-5, IL-6, IL-8, IL-10 and IL-13, but particularly for use in the treatment of IL-4 and/or IL-8 and/or IgE mediated diseases or disorders and/or eosinophilic diseases or disorders.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61P 11/06 - Antiasthmatiques
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 37/02 - Immunomodulateurs
• A61P 37/08 - Agents antiallergiques